Proteinaceous bacterial toxins and pathogenesis of sepsis syndrome and septic shock: the unknown connection

1994 ◽  
Vol 183 (6) ◽  
Author(s):  
Sucharit Bhakdi ◽  
Friedrich Grimminger ◽  
Norbert Suttorp ◽  
Dieter Walmrath ◽  
Werner Seeger
1994 ◽  
Vol 183 (3) ◽  
Author(s):  
Sucharit Bhakdi ◽  
Friedrich Grimminger ◽  
Norbert Suttorp ◽  
Dieter Walmrath ◽  
Werner Seeger

1992 ◽  
Vol 7 (2) ◽  
pp. 90-100 ◽  
Author(s):  
Margaret M. Parker ◽  
Mitchell P. Fink

The incidence of sepsis and septic shock has been increasing dramatically over the past 10 years. Despite advances in antimicrobial therapy, the mortality of septic shock remains very high. We review the clinical manifestations of sepsis and septic shock and describe the cardiovascular manifestations. Pathophysiology of the cardiovascular changes is discussed, and mediators believed to be involved in the pathogenesis are reviewed. Management of septic shock is also discussed, including antimicrobial therapy, supportive care, and adjunctive treatment aimed at affecting the mediators involved in producing the sepsis syndrome.


1993 ◽  
Vol 21 (7) ◽  
pp. 1012-1019 ◽  
Author(s):  
GEORG KREYMANN ◽  
SEBASTIAN GROSSER ◽  
PETER BUGGISCH ◽  
CLAUS GOTTSCHALL ◽  
STEPHAN MATTHAEI ◽  
...  

1996 ◽  
Vol 22 (3) ◽  
pp. 213-219 ◽  
Author(s):  
T. Lherm ◽  
G. Troché ◽  
M. Rossignol ◽  
P. Bordes ◽  
J. F. Zazzo

Author(s):  
S. Bhakdi ◽  
I. Walev ◽  
D. Jonas ◽  
M. Palmer ◽  
U. Weller ◽  
...  

2011 ◽  
Vol 31 (6) ◽  
pp. 16-26 ◽  
Author(s):  
Tania Christine Yarema ◽  
Spencer Yost

Septic shock is the 13th leading cause of death in the United States. The rate of severe sepsis nearly doubled and mortality increased more than 60% during the 10-year period ending in 2003. Systemic inflammatory response syndrome has noninfectious and infectious causes. Noninfectious ones include burns, trauma, severe pancreatitis, and therapy with monoclonal antibodies or immunomodulatory drugs such as interleukin 2. Progression from sepsis syndrome to septic shock is caused by a series of immune responses. As an infectious injury progresses, host activation of the coagulation, immunological, and stress response systems ensues, resulting in tissue hypoperfusion and organ failure. Early studies with small numbers of patients suggest that treatment with low-dose corticosteroids has marked beneficial effects on shock reversal, the immune system, and the hemodynamic profile. Low-dose corticosteroids should only be administered to a subset of patients with septic shock who are unresponsive to fluid replacement and vasopressor therapy.


2018 ◽  
Vol 65 (4) ◽  
pp. 315-320
Author(s):  
N B Mathur ◽  
Bijaylaxmi Behera

Abstract Objective To determine the time to normalization of procalcitonin (PCT) levels and duration of antibiotics in neonatal sepsis. Methods A prospective observational study design was used. The participants included were neonates with sepsis. The primary outcome measure was time to normalization of PCT levels and duration of antibiotics following clinical resolution. Results Time to normalization of PCT levels was 9.6 ± 4.2 days in neonates with septic shock, 6.2 ± 2.5 days in neonates without shock, 9.6 ± 3.1 days in neonates with culture-positive sepsis and 6.4 ± 3.1 days in neonates with culture-negative sepsis. Time to normalization of PCT levels according to the stage of systemic inflammatory response syndrome was 5.8 ± 2.8 days in neonates with sepsis, 6.1 ± 3.1 days in those with sepsis syndrome, 6.3 ± 3.3 days in those with early septic shock and 9.4 ± 3.6 days in those with multiorgan dysfunction syndrome. There was no morbidity and mortality in any neonate in the 4-week follow-up. Conclusion The duration of antibiotics can be determined by observing the time to normalization of PCT following clinical resolution of sepsis.


2020 ◽  
Author(s):  
Giorgio Berlot ◽  
Alice Scamperle ◽  
Tatiana Istrati ◽  
Roberto Dattola ◽  
Irene Longo ◽  
...  

Abstract. Objective: to assess the variations of the blood levels of immunoglobulins (Ig) in septic shock patients treated with an Ig preparation enriched in IgM and IgA (eIg). Design: The blood levels of Ig in survivors (S) and non-survivors (NS) of a group of septic shock patients were measured before the initial administration (D0) and one (D1), four (D4) and seven (D7) days thereafter. The SAPS II score, the capillary permeability, the primary site of infection, the antibiotic appropriateness, the microorganisms isolated and the outcome at 28 days were also assessed. Results: In the interval D0-D7 the IgM increased significantly only in the S while remained stable in NS; the IgA significantly increased in both groups; the IgG did not vary significantly in both groups. At D7 the capillary permeability significantly decreased in S but not in NS. Conclusions: The kinetics of the different classes of Ig after eIg were different between S and NS. This could be related either to (a) different capillary permeability in the two groups and/or (b) higher Ig consumption in NS. Further studies to confirm the benefits of eIg in the treatment of sepsis syndrome, to define the specific target population and the correct eIg dose are warranted.


Sign in / Sign up

Export Citation Format

Share Document